Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Revenue
Tibet Rhodiola Pharmaceutical Holding Co
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Revenue
¥3.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
25%
|
CAGR 10-Years
8%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Revenue
¥591.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Revenue
¥260.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Revenue
¥151.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Revenue
¥49.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Revenue
¥40.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue?
Revenue
3.1B
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Revenue amounts to 3.1B CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was 23%. The average annual Revenue growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 32% over the past three years , 25% over the past five years , and 8% over the past ten years .